confers oncogenic effects in prostate cancer.

Identification oncogenes is fundamental to revealing the molecular basis of cancer. Here, we found that is overexpressed in human prostate cancer cells and prostate tumors, but its expression is absent in normal prostate epithelial cells and low in benign prostatic hyperplasia. is a FOX transcription factor family member and tightly associated with vocal development. To date, little is known regarding the link of to prostate cancer. We observed that high expression and frequent amplification are significantly associated with high Gleason score. Ectopic expression of induces malignant transformation of mouse NIH3T3 fibroblasts and human prostate epithelial cell RWPE-1. Conversely, knockdown suppresses the proliferation of prostate cancer cells. Transgenic overexpression of in the mouse prostate causes prostatic intraepithelial neoplasia. Overexpression of aberrantly activates oncogenic MET signaling and inhibition of MET signaling effectively reverts the -induced oncogenic phenotype. CUT&Tag assay identified FOXP2-binding sites located in and its associated gene . Additionally, the novel recurrent fusion identified in prostate tumors results in high expression of truncated FOXP2, which exhibit a similar capacity for malignant transformation. Together, our data indicate that is involved in tumorigenicity of prostate.